Pitcairn CO Novo Nordisk A S Transaction History

Pitcairn CO

$1.63 Billion
Q1 2025

A detailed history of Pitcairn CO transactions in Novo Nordisk A S stock. As of the latest transaction made, Pitcairn CO holds 14,465 shares of NVO stock, worth $992,298. This represents 0.06% of its overall portfolio holdings.

Number of Shares

14,465

Previous 14,910 2.98%

Holding current value

$992,298

Previous $1.28 Million 21.68%

% of portfolio

0.06%

Previous 0.08%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 09, 2025	SELL	$69.3 - $90.95 $30,838 - $40,472	-445 Reduced 2.98%	14,465 $1 Million
Q4 2024 Feb 12, 2025	BUY	$85.0 - $120.04 $44,795 - $63,261	527 Added 3.66%	14,910 $1.28 Million
Q3 2024 Nov 12, 2024	SELL	$119.07 - $145.42 $120,141 - $146,728	-1,009 Reduced 6.56%	14,383 $1.71 Million
Q2 2024 Aug 13, 2024	BUY	$122.71 - $146.91 $58,409 - $69,929	476 Added 3.19%	15,392 $2.2 Million
Q1 2024 May 13, 2024	BUY	$102.11 - $135.92 $1.52 Million - $2.03 Million	14,916 New	14,916 $1.92 Million
Q4 2023 Jul 09, 2024	SELL	$87.78 - $105.45 $71,628 - $86,047	-816 Reduced 5.47%	14,100 $1.46 Billion
Q3 2023 Jul 09, 2024	SELL	$90.94 - $199.54 $590,382 - $1.3 Million	-6,492 Reduced 43.52%	8,424 $766 Million
Q2 2023 Aug 11, 2023	SELL	$155.98 - $172.65 $10,450 - $11,567	-67 Reduced 1.83%	3,596 $581,000
Q1 2023 May 05, 2023	BUY	$132.34 - $159.14 $101,769 - $122,378	769 Added 26.57%	3,663 $582,000
Q4 2022 Feb 13, 2023	BUY	$102.55 - $135.33 $6,153 - $8,119	60 Added 2.12%	2,894 $391,000
Q3 2022 Nov 10, 2022	BUY	$95.28 - $116.93 $62,313 - $76,472	654 Added 30.0%	2,834 $282,000
Q2 2022 Aug 12, 2022	BUY	$103.24 - $121.81 $225,063 - $265,545	2,180 New	2,180 $243,000

Others Institutions Holding NVO

# of Institutions

1,769

Shares Held

330M

Call Options Held

11.3M

Put Options Held

15.5M

View Full List

About NOVO NORDISK A S

Ticker NVO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,257,289,984
Market Cap $155B
Description
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...

More about NVO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pitcairn CO, based on Form 13F filings with the SEC.

News

Stay updated on Pitcairn CO with notifications on news.

Account